From a translational perspective, our findings affirm that BCL-2 immunohistochemical evaluation could be incorporated into standard MDS workups to help refine prognostic stratification and potentially identify those who might benefit most from BCL-2-targeted regimens. This evidence concerns the gene BCL2 and myelodysplastic syndrome.